Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126887821 | 12688782 | 1 | I | 20160816 | 20160825 | 20160825 | EXP | IT-BAUSCH-BL-2016-020420 | BAUSCH AND LOMB | MAFFINI E, GIACCONE L, FESTUCCIA M, BRUNELLO L, BUONDONNO I, FERRERO D. RUXOLITINIB IN STEROID REFRACTORY GRAFT-VS.-HOST DISEASE: A CASE REPORT. JOURNAL OF HEMATOLOGY AND ONCOLOGY. 2016;9(1):. | 51.00 | YR | M | Y | 0.00000 | 20160825 | MD | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126887821 | 12688782 | 1 | PS | BUDESONIDE. | BUDESONIDE | 1 | Oral | U | 205613 | 3 | MG | TID | |||||||
| 126887821 | 12688782 | 2 | SS | CICLOSPORIN | CYCLOSPORINE | 1 | Unknown | (1.5 MG/KG TWICE DAILY, FROM DAY -1) | U | 0 | 1.5 | MG/KG | BID | ||||||
| 126887821 | 12688782 | 3 | SS | MYCOPHENOLATE MOFETIL. | MYCOPHENOLATE MOFETIL | 1 | Intravenous (not otherwise specified) | 0 | 1 | G | TID | ||||||||
| 126887821 | 12688782 | 4 | C | METHOTREXATE. | METHOTREXATE | 1 | 15 MG/M2, 24 HOURS AFTER TRANSPLANT | U | 0 | 15 | MG/M**2 | ||||||||
| 126887821 | 12688782 | 5 | C | METHOTREXATE. | METHOTREXATE | 1 | 10 MG/M2 ON DAYS 3, 6, AND 11 | U | 0 | 10 | MG/M**2 | ||||||||
| 126887821 | 12688782 | 6 | C | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | (60 MG/KG/DAY; DAYS -3 AND -2) | 0 | 60 | MG/KG | QD | ||||||||
| 126887821 | 12688782 | 7 | C | THYMOGLOBULIN | LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN | 1 | (2.5 MG/KG ON DAYS -3 AND -2) | 0 | 2.5 | MG/KG | |||||||||
| 126887821 | 12688782 | 8 | C | BUSULFAN. | BUSULFAN | 1 | (3.2 MG/KG/DAY; DAYS -7 TO -4) | 0 | 3.2 | MG/KG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126887821 | 12688782 | 1 | Product used for unknown indication |
| 126887821 | 12688782 | 2 | Prophylaxis against graft versus host disease |
| 126887821 | 12688782 | 3 | Product used for unknown indication |
| 126887821 | 12688782 | 4 | Prophylaxis against graft versus host disease |
| 126887821 | 12688782 | 5 | Prophylaxis against graft versus host disease |
| 126887821 | 12688782 | 6 | Product used for unknown indication |
| 126887821 | 12688782 | 7 | Prophylaxis against graft versus host disease |
| 126887821 | 12688782 | 8 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126887821 | 12688782 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126887821 | 12688782 | Drug ineffective |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |